Progyny Q4 2022 Earnings Report $14.34 +0.15 (+1.06%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Progyny EPS ResultsActual EPS$0.03Consensus EPS $0.02Beat/MissBeat by +$0.01One Year Ago EPS$0.15Progyny Revenue ResultsActual Revenue$214.32 millionExpected Revenue$211.78 millionBeat/MissBeat by +$2.54 millionYoY Revenue Growth+68.00%Progyny Announcement DetailsQuarterQ4 2022Date2/27/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingPGNY Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Progyny Earnings HeadlinesPGNY Stockholders: Robbins LLP is Investigating the Officers and Directors of Progyny, Inc. to Determine if They Breached Fiduciary Duties Owed to ShareholdersDecember 18, 2024 | prnewswire.comJohnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) ShareholdersDecember 18, 2024 | globenewswire.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 22, 2024 | Crypto 101 Media (Ad)Progyny, Inc. (NASDAQ:PGNY) Receives $25.00 Average PT from AnalystsDecember 13, 2024 | americanbankingnews.comRobbins LLP Informs Progyny, Inc. Stockholders that it is Investigating the Officers and Directors of PGNY to Determine if They Breached Fiduciary Duties Owed to ShareholdersDecember 11, 2024 | globenewswire.comJohnson Fistel has Commenced an Investigation on Behalf of Progyny (PGNY) ShareholdersDecember 3, 2024 | globenewswire.comSee More Progyny Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Progyny? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Progyny and other key companies, straight to your email. Email Address About ProgynyProgyny (NASDAQ:PGNY), a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.View Progyny ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
